UPSC Exam Preparation: Topic of the Day – National Biopharma Mission UPSC
The government of India launched the Innovate in India (I3) program under the National Biopharma Mission. It is the first ever industry-academia mission to speed up biopharmaceutical development in India. It aims at plugging-in the gaps in the pharmaceutical sector such as,
- Unconnected centres of excellence.
- Lower focus on translational research.
- Staggered funding.
Innovate in India Program
- It is a flagship program of Government of India and has received financial assistance from the World Bank.
- It will build sustainable networks for collaboration between the industry, academia and in turn support the entrepreneurial ecosystem.
- The program is expected to widen India’s share (currently 2.8%) to 5% in the global biopharmaceutical market resulting in additional business opportunity.
National Biopharma Mission
- The pharmaceutical industry holds a promising future for India, and the National Biopharma Mission is anticipated to be the game changer for Indian Pharmaceutical Industries.
- The mission aspires to create a conducive ecosystem to encourage entrepreneurship and indigenous manufacturing in the sector by strengthening technology transfer capabilities in the private and the public sector.
- It aims to make India a hub for design and development of affordable, novel and effective biopharmaceutical products and solutions.
- The mission strives to encourage entrepreneurship to transform the health standards of the people of India through affordable medicines.
- A Public Sector Undertaking of Department of Biotechnology – Biotechnology Industry Research Assistance Council (BIRAC) is involved in the implementation of the mission. It is expected to integrate expertise from national and international corridors to provide strategic guidance and direction to yield promising results through the product development value chain.
Though India is an active participant in the global biopharmaceutical market and has contributed towards manufacture of low-cost life-saving drugs such as heart valve prosthesis, affordable insulin, rotavirus vaccine etc., it is still 10-15 years behind its peers and faces stiff competition from Korea, China etc. Therefore there was an urgent need for innovation, creation and facilitation of scientific discoveries.
|The antibiotic red line of control|
|Measles and Rubella Campaign|